Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary) ; Corticosteroids
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms ESTEEM-2
  • Sponsors Amgen; Celgene Corporation
  • Most Recent Events

    • 21 Mar 2023 Results From ESTEEM 1 and ESTEEM 2 analyzing efficacy of Apremilast in Patients With Moderate-to-Severe Plaque Psoriasis Across Weight and BMI Subgroups, resented at the American Academy of Dermatology annual Meeting 2023
    • 25 Apr 2021 Results assessing APR on scalp and nail psoriasis in patients with and without dermatology investigator-reported PsA history in moderate-to-severe psoriasis from ESTEEM 1 & 2 and LIBERATE trials presented at the American Academy of Dermatology Virtual Meeting Experience 2021
    • 12 Sep 2018 According to a Celgene Corporation media release, results of a post hoc sub-analysis of data from the ESTEEM 1 and 2 and phase 4 UNVEIL trials were presented at the 27th European Academy of Dermatology and Venereology (EADV) Congress.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top